165 related articles for article (PubMed ID: 8700148)
1. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.
Balzarini J; Pelemans H; Aquaro S; Perno CF; Witvrouw M; Schols D; De Clercq E; Karlsson A
Mol Pharmacol; 1996 Aug; 50(2):394-401. PubMed ID: 8700148
[TBL] [Abstract][Full Text] [Related]
2. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
[TBL] [Abstract][Full Text] [Related]
3. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Balzarini J; Karlsson A; De Clercq E
Mol Pharmacol; 1993 Oct; 44(4):694-701. PubMed ID: 7694068
[TBL] [Abstract][Full Text] [Related]
5. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.
Pelemans H; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2000 May; 57(5):954-60. PubMed ID: 10779379
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues.
Balzarini J; Velazquez S; San-Felix A; Karlsson A; Perez-Perez MJ; Camarasa MJ; De Clercq E
Mol Pharmacol; 1993 Jan; 43(1):109-14. PubMed ID: 7678689
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
9. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).
Balzarini J; Pérez-Pérez MJ; Vélazquez S; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5470-4. PubMed ID: 7539917
[TBL] [Abstract][Full Text] [Related]
11. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
[TBL] [Abstract][Full Text] [Related]
12. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.
Mellors JW; Dutschman GE; Im GJ; Tramontano E; Winkler SR; Cheng YC
Mol Pharmacol; 1992 Mar; 41(3):446-51. PubMed ID: 1372083
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus.
Balzarini J; Brouwer WG; Dao DC; Osika EM; De Clercq E
Antimicrob Agents Chemother; 1996 Jun; 40(6):1454-66. PubMed ID: 8726019
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Golebiewski WM; Graham L; Turpin JA; Rice WG; Fliakas-Boltz V; Buckheit RW
J Med Chem; 1996 Aug; 39(16):3217-27. PubMed ID: 8759644
[TBL] [Abstract][Full Text] [Related]
16. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.
Balzarini J; Pelemans H; Esnouf R; De Clercq E
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):255-60. PubMed ID: 9491916
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
18. [Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].
de Clercq E; Snoeck R
Pathol Biol (Paris); 1993 Mar; 41(3):230-6. PubMed ID: 7687340
[No Abstract] [Full Text] [Related]
19. Biochemical and genetical analysis of AZT-resistant HIV-mutants.
Biesert L; Zimmermann F; Schröder B; Matthes E; Suhartono H; Dietrich U; Rübsamen-Waigmann H
Behring Inst Mitt; 1991 Jul; (89):74-80. PubMed ID: 1930105
[TBL] [Abstract][Full Text] [Related]
20. The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A.
Auwerx J; Rodríguez-Barrios F; Ceccherini-Silberstein F; San-Félix A; Velázquez S; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
Mol Pharmacol; 2005 Sep; 68(3):652-9. PubMed ID: 15961674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
